We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo.  Then we discuss new research from University of California, San Diego, that used machine learning to identify networks of genes that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.   

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  

Listed below are links to the GEN stories referenced in this episode of Touching Base:  

Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance  

Uduak Thomas, GEN, October 6, 2025  

AI in Protein Design: Hype vs. Reality Explained by David Baker  

By Fay Lin, PhD, GEN, October 20, 2025  

Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle  

By Fay Lin, PhD, GEN, October 14, 2025  

AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct  

GEN, October 20, 2025  

The State of AI in Drug Discovery Registration  

Touching Base Podcast  

Hosted by Corinna Singleman, PhD  

Behind the Breakthroughs  

Hosted by Jonathan D. Grinstein, PhD 

Hosted on Acast. See acast.com/privacy for more information.